MYGN — Myriad Genetics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual cashflow statement for Myriad Genetics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 June 30th	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-200	-27.2	-112	-263	-127
Depreciation
Deferred Taxes
Non-Cash Items	129	-106	85.3	83.8	115
Unusual Items
Other Non-Cash Items
Changes in Working Capital	115	120	-102	10.7	-54.4
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities	60.7	18.2	-106	-111	-8.7
Capital Expenditures	-10.2	-18	-45.3	-73.3	-29.7
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	29.5	292	-32.2	105	17.8
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities	19.3	274	-77.5	31.9	-11.9
Financing Cash Flow Items	-4.9	-4.5	-3.7	-1.7	0
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-10	-151	-8	153	-7.4
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	70.5	141	-192	74.5	-29